Rockville, MD, June 16, 2016 – The Sanofi Pasteur-Aeras Joint Steering Committee for the Phase 2 trial (C-040-404/TUB09) convened on 14 June 2016 to review and discuss the recommendations of the study’s independent Data Monitoring Committee (DMC).
Aeras applauds the Final Report and Recommendations released this week by the U.K. Review on Antimicrobial Resistance (Review) that highlights the extreme global health threat of antimicrobial resistance (AMR), including the threat of multidrug-resistant tuberculosis (MDR-TB).
Healthcare Workers Face Up To Six Times the Risk of Drug-Resistant Tuberculosis as General Population
New research suggests urgent action needed to combat tuberculosis among healthcare workers in poorer countries Globally, healthcare workers face three times the risk of contracting tuberculosis as the general population, and the risks of multidrug-resistant disease is higher still: up to six times higher for healthcare workers in South Africa, according to new reports that are part of a healthcare worker-focused supplement in the journal Clinical Infectious Diseases. Up to one-third of affected healthcare workers die of this airborne disease.
A team of scientists led by Oxford University have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis. The researchers have identified new biomarkers for Tuberculosis (TB) which have shown for the first time why immunity from the widely used Bacillus Calmette-Guérin (BCG) vaccine is so variable. The biomarkers will also provide valuable clues to assess whether potential new vaccines could be effective.
Aeras and the Human Vaccines Project announced a new collaboration aimed at accelerating the development of vaccines and immunotherapies for key global populations. The Human Vaccines Project is a new global initiative that brings together leading academic centers, industry, nonprofits and governments in a global discovery consortium to solve the primary scientific hurdles impeding the development of vaccines and immune-driven therapies.